SMARCB1 and renal cell adenocarcinoma: Nomenclature modifications were observed in the context of papillary and clear cell renal cancer: HLRCC nomenclature was modified to FH-deficient RCC, and renal medullary cancer has been revised to SMARCB1-deficient RCC.